Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - QIAGEN reported a strong start to the year with a 6% overall growth rate in the second quarter, indicating resilience despite market volatility [1] - The company's business model is heavily consumer-oriented, with 85% to 90% of revenues derived from consumer-related activities [2] Revenue Breakdown - 50% of QIAGEN's revenues are generated from clinical settings and lab organizations, while the other 50% comes from life sciences, including pharmaceutical and applied testing customers [2]